Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AGYB | ISIN: US04280A1007 | Ticker-Symbol: HDP1
Tradegate
19.11.24
20:47 Uhr
17,540 Euro
-0,225
-1,27 %
1-Jahres-Chart
ARROWHEAD PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ARROWHEAD PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
17,76518,06015:29
0,0000,00015:28

Aktuelle News zur ARROWHEAD PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ARROWHEAD PHARMACEUTICALS Aktie jetzt für 0€ handeln
DiArrowhead Pharmaceuticals submits plozasiran NDA to treat FCS9
05.11.Arrowhead targets rare disease patients, pushing message that hope is on the horizon5
08.10.Arrowhead Pharma maintains Buy rating from TD Cowen after R&D day insights6
08.10.Arrowhead Pharma behält Kaufempfehlung von TD Cowen nach Einblicken vom F&E-Tag36
08.10.Arrowhead Pharma behält Overweight-Bewertung von Piper Sandler12
07.10.ARWR stock touches 52-week low at $18.14 amid market challenges7
11.09.FDA grants breakthrough therapy status to Arrowhead's plozasiran14
04.09.Arrowhead Pharma maintains stock target, buy rating after trial success7
03.09.Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug7
03.09.Arrowhead's RNAi therapeutic plozasiran shows promise in familial chylomicronaemia syndrome4
03.09.Arrowhead fires off phase 3 data in rare metabolic disease ahead of market clash with Ionis6
03.09.Why Arrowhead Pharmaceuticals Is Rising In Pre-market?3
21.08.Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome420Company hosting a virtual analyst and investor event on September 3, 2024, at 8:00 am EDT to discuss results Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present...
► Artikel lesen
16.08.Zealand Pharma, Arrowhead advance obesity drugs; Bluebird narrows guidance16
15.08.Arrowhead announces push into obesity space with two gene therapies5
15.08.Arrowhead Pharma maintains stock price target with Overweight rating1
14.08.After clearing out heart disease drug, Arrowhead maps out obesity development plans2
09.08.Earnings call: Arrowhead Pharmaceuticals aims for 20 clinical products by 20257
08.08.Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results142PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 third quarter ended June 30, 2024. The Company is hosting...
► Artikel lesen
26.06.Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up9
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1